Delivering on Diversity: Clinical Trials and Healthcare Access

Clinical trials help people access tomorrow’s treatments today. In the age of precision medicine and tumor profiling, this statement is particularly true for oncology patients. According to a recent ProPublica article, even in Phase I trials, 20% of clinical trial participants now see a reduction in tumor size, compared with 5% of participants in the 1990s.

Continue reading

Delivering on Diversity: Tuskegee and what it means for minority participation in medical research today

Every conversation about minority participation in medical research inevitably winds up with the “T” word – Tuskegee.

Continue reading

Research Pioneers: Meet Allison Kalloo

At Antidote, we aim to make it easy for researchers and patients to connect. And a big part of that work is creating opportunities for people to learn more about medical research and dispelling myths about medical research participation, both for patients and researchers.

Continue reading

Relentless Health Value Podcast: How Being Patient-Centric, Not Trial-Centric, Can Improve Clinical Trial Recruitment and Retention

The clinical trial landscape is shifting — but is it enough? Antidote’s Founder, Pablo Graiver, was recently interviewed for the Relentless Health Value podcast to discuss this fundamental question.

Continue reading

A brush of inspiration: A talk with patient advocate Regina Holliday

The hall was full of people clad in conference attire: black suits, white shirts, and, for some, an adventurous pop of color in a shoe or a tie.

Continue reading

Get our latest posts in your inbox